Effect of age and glycaemic control on the association between fibrinogen and risk of acute coronary events after transient ischaemic attack or stroke

Cerebrovascular Diseases

Volumn 25, Issue 1-2, 2008, Pages 136-143

  Howard, S C ^a   Algra, A ^b   Rothwell, P M ^a,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

Coronary disease; Fibrin; Fibrinogen; Glucose

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; FIBRINOGEN; GLUCOSE; PLACEBO;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; GLYCEMIC CONTROL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STROKE; TRANSIENT ISCHEMIC ATTACK;

EID: 39549102600     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000112324     Document Type: Article

References (39)

1. Drouet L: Fibrinogen: a treatable risk factor? Cerebrovasc Dis 1996;6:2-6.
2. Kannel WB: Influence of fibrinogen on cardiovascular disease. Drugs 1997;54(suppl 3):32-40.
3. Harley SL, Powell JT: Fibrinogen upregulates the expression of monocyte chemoattractant protein-1 in human saphenous vein endothelial cells. Biochem J 1999;341:739-744.
4. Ernst E, Resch KL: Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993;118:956-963.
5. Maresca G, Di Blasio A, Marchioli R, Di Minno G: Measuring plasma fibrinogen to predict stroke and myocardial infarction. Arterioscler Thromb 1999;19:1368-1377.
6. Fibrinogen Studies Collaboration: Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005;294:1799-1809.
7. Wilhelmsen L, Svardsudd K, Korsan-Bengsten K, Larsson B, Welin L, Tibblin G: Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984;311:501-505.
8. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB: Fibrinogen and risk of cardiovascular disease. JAMA 1987;258:1183-1186.
9. Lowe G, Rumley A, Norrie J, Ford I, Shepherd J, Cobbe S, Macfarlane P, Packard C: Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study. Thromb Haemost 2000;84:553-558.
10. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE: Prospective study of hemostatic factors and incidence of coronary heart disease. Circulation 1997;96:1102-1108.
11. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JC: Hemostatic risk factors and risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995;332:635-641.
12. Smith FB, Lee AJ, Fowkes GR, Price JF, Rumley A, Lowe GDO: Hemostatic Factors as predictors of ischaemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb 1997;17:3321-3325.
13. Tanne D, Benderly M, Goldbourt U, Boyko V, Brunner D, Graff E, Reicher-Reiss H, Shotan A, Mandelzweig L, Behar S; the Bezafibrate Infarction Prevention Study Group: A prospective study of plasma fibrinogen levels and the risk of stroke among participants in the Bezafibrate Infarction Prevention Study. Am J Med 2001;111:457-463.
14. Rothwell PM, Howard SC, Power DA, Gutnikov SA, Algra A, van Gijn J, Clark TG, Murphy MFG, Warlow CP; the Cerebrovascular Cohort Studies Collaboration: Fibrinogen concentration and risk of ischaemic stroke and acute coronary events in 5113 patients with transient ischaemic attack and minor ischaemic stroke. Stroke 2004;35:2300-2305.
15. Meade TW: Fibrinogen measurement to assess the risk of arterial thrombosis in individual patients: yes. J Thromb Haemost 2005;3:632-634.
16. Lowe GDO: Fibrinogen measurement to assess the risk of arterial thrombosis in individual patients: not yet. J Thromb Haemost 2005;3:635-637.
17. Scrutton MC, Ross-Murphy SB, Bennett GM, Stirling Y, Meade TW: Changes in clot deformability - a possible explanation for the epidemiological association between plasma fibrinogen concentration and myocardial infarction. Blood Coagul Fibrinolysis 1994;5:719-723.
18. Fatah K, Silveria A, Tornvall P, Karpe F, Blomback M, Hamsten A: Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 1996;76:535-540.
19. Fatah K, Hamsten A, Blomback B, Blomback M: Fibrin gel network characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost 1992;68:130-135.
20. Lim BCB, Ariens RAS, Carter AM, Weisel JW, Grant PJ: Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet 2003;361:1424-1431.
21. Jorneskog G, Egberg N, Fagrell B, Fatah K, Hessel B, Johnsson H, Brismar K, Blomback M: Altered properties of the fibrin gel structure in patients with IDDM. Diabetologica 1996;39:1519-1523.
22. Dunn EJ, Ariens RA, Grant PJ: The influence of type 2 diabetes on fibrin structure and function. Diabetologica 2005;48:1198-1206.
23. Dunn EJ, Ariens RA: Fibrinogen and fibrin clot structure in diabetes. Herz 2004;29:470-479.
24. Krantz S, Lober M, Thiele M, Teuscher E: Properties of nonenzymatically glycated plasma fibrinogens. Exp Clin Endocrinol 1987;90:37-45.
25. Mirshahi M, Soria J, Soria C, Bertrand O, Mirshahi M, Basdevant A: Glycosylation of human fibrinogen and fibrin in vitro. Its consequences on the properties of fibrin(ogen). Thromb Res 1987;48:279-289.
26. Brownlee M, Vlassara H, Cerami A: Nonenzymatic glycosation reduces the susceptibility of fibrin to degradation by plasmin. Diabetes 1983;32:680-684.
27. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson JD, Thompson SG: Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986;ii:533-537.
28. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB: Fibrinogen and risk of cardiovascular disease: the Framingham study. JAMA 1987;258:1183-1186.
29. UK-TIA Study Group: The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991;54:1044-1054.
30. The Dutch TIA Study Group: A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischaemic attack or minor ischaemic stroke. N Eng J Med 1991;325:1261-1266.
31. Clark TG, Murphy MFG, Rothwell PM: Long-term risks of stroke, myocardial infarction, and vascular death in patients with a non-recent transient ischaemic attack. JNNP 2003;74:577-580.
32. Ellis BC, Stransky A: A quick and accurate method for the determination of fibrinogen in plasma. J Lab Clin Med 1961;58:477-488.
33. Cederholm-Williams SA: Fibrinogen assay technique suitable for large-scale studies; in Lowe GD, Douglas JT, Forbes CD, Henschen A (eds): Fibrinogen 2: Biochemistry, Physiology and Clinical Relevance, Proceedings of the Fibrinogen Workshop, Glasgow, April 1987. Int Congr Ser. New York, Elsevier, 1987, vol 745, pp 81-85.
34. Clauss A: Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol 1957;17:237-246.
35. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-1197.
36. Rudnicka AR, Mt-Isa S, Meade TW: Associations of plasma fibrinogen and factor VII clotting activity with coronary heart disease and stroke: prospective cohort study from the screening phase of the Thrombosis Prevention Trial. J Thromb Haemost 2006;4:2405-2410.
37. De Stavola BL, Meade T: Long-term effects of haemostatic variables on fatal coronary heart disease: 30 year results from the first prospective Northwick Park Heart Study (NPHS-1). J Thromb Haemost 2006, Epub ahead of print.
38. Johnson P, Rosewell M, James MA: How good is the management of vascular risk after stroke, transient ischaemic attack or carotid endarterectomy? Cerebrovasc Dis 2007;23:156-161.
39. Fuller WA: Measurement Error Models. New York, John Wiley & Sons, 1987.